Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
194 participants
INTERVENTIONAL
2007-11-30
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The present study evaluates the efficacy of the ATP One Shot algorithm for the termination of fast VT episodes. 200 patients with secondary prophylactic ICD indication will be followed for 18 months. Spontaneous episodes detected in the VF-zone of the ICD will be evaluated with regard to cycle length, episode duration and course of device therapy.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main objective of the study is the assessment of the efficacy of the ATP One Shot algorithm for the termination of fast VT episodes. To this end, spontaneous episodes detected in the VF-zone of the ICD are evaluated with regard to cycle length, episode duration and course of device therapy. In the context of the study, a confirmatory (hypothesis-testing) primary problem is investigated. The goal is to measure the time to first adequate shock therapy for episodes detected in the VF-zone of the device and to analyze the hazard ratio of the standard ICD setting compared to a therapy with the ATP One Shot algorithm.
The clinical project is conducted as randomized prospective multicenter study. The chronological order and the scope of the follow-ups meet the medical standard according to the international guidelines. A center-based, stratified block randomization will be performed. In approximately 50% of the patients the ATP One Shot algorithm will be activated, while the other 50% will be randomized into the control group.
A total of about 20 European investigational sites will participate in the study. Each center should enroll about 10 patients who will be followed for 18 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
programming of VF therapy: ATP (antitachycardia pacing) One Shot ON
ATP One Shot ON
The new antitachycardia pacing algorithm "ATP One Shot" attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery
2
programming of VF therapy: ATP (antitachycardia pacing) One Shot OFF
ATP One Shot OFF
Standard defibrillation shock delivery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ATP One Shot ON
The new antitachycardia pacing algorithm "ATP One Shot" attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery
ATP One Shot OFF
Standard defibrillation shock delivery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients not capable of participating in the follow-ups
* Minors and pregnant women
* Patients who are already enrolled in another study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biotronik SE & Co. KG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jörg Otto Schwab, PD Dr.
Role: STUDY_CHAIR
University Hospital Bonn, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medizinische Abteilung, LKH Bruck
Bruck / Mur, , Austria
Innere Medizin - Kardiologie, Universitätsklinik Innsbruck
Innsbruck, , Austria
Med. Abteilung, AKH Linz
Linz, , Austria
Cardiology, Satakunta Central Hospital
Pori, , Finland
Klinik für Innere Medizin, Vivantes Humboldt Klinikum
Berlin, , Germany
Medizinische Klinik II, Universitätsklinikum Bonn
Bonn, , Germany
Medizinische Klinik I, Ev. Krankenhaus
Holzminden, , Germany
Medizinische Klinik, Kreiskrankenhaus
Neustadt / Aisch, , Germany
Kardiologie, DRK Krankenhaus Mölln
Ratzeburg, , Germany
Kardiologische Praxis Dr. Placke
Rostock, , Germany
Innere Medizin - Kardiologie, Klinikum Uckermark
Schwedt, , Germany
Kliniken Villingen Schwenningen, Klinik für Innere Medizin III, Kardiologie
Villingen, , Germany
Medizinische Klinik I, St-Josefs-Hospital
Wiesbaden, , Germany
Cardiology, Rabin MC
Petah Tikva, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TA080
Identifier Type: -
Identifier Source: org_study_id